Liquidia: United Therapeutics dismisses '793 Patent claims in PH-ILD litigation; '327 Patent remains

Liquidia Corp

On Jan 22, 2024, United Therapeutics stipulated to dismiss all claims related to the '793 Patent in the New Hatch-Waxman Litigation.
Only claims related to the '327 Patent remain; Liquidia asserts the '327 Patent does not entitle a 30-month regulatory stay.
The dismissal does not affect the injunction issued in the Original Hatch-Waxman Litigation (filed June 2020).
Liquidia's motion to set aside the original injunction is fully briefed; awaiting the District Court's decision.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.